14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 ZNTL stock ended at $11.71. This is 5.40% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 5.76% from a day low at $11.45 to a day high of $12.11.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Zentalis Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Mar 28, 2024 $15.28 $16.08 $15.22 $15.76 579 811
Mar 27, 2024 $14.23 $15.24 $14.07 $15.19 570 396
Mar 26, 2024 $13.83 $14.36 $13.64 $14.09 455 914
Mar 25, 2024 $13.50 $14.02 $13.37 $13.58 650 011
Mar 22, 2024 $13.84 $13.85 $13.54 $13.65 336 067
Mar 21, 2024 $13.80 $14.26 $13.67 $13.71 436 864
Mar 20, 2024 $14.14 $14.14 $13.15 $13.70 517 992
Mar 19, 2024 $13.84 $14.14 $13.59 $13.92 739 475
Mar 18, 2024 $14.25 $14.26 $13.70 $13.86 673 173
Mar 15, 2024 $14.08 $14.69 $13.71 $14.32 2 306 959
Mar 14, 2024 $15.26 $15.45 $13.80 $14.11 1 059 003
Mar 13, 2024 $14.69 $15.39 $14.43 $15.35 1 075 142
Mar 12, 2024 $13.85 $15.05 $13.57 $14.79 1 013 853
Mar 11, 2024 $15.44 $15.88 $13.45 $13.94 1 618 162
Mar 08, 2024 $15.18 $15.77 $15.17 $15.39 670 522
Mar 07, 2024 $14.66 $15.14 $14.36 $14.85 1 443 018
Mar 06, 2024 $14.39 $14.61 $14.12 $14.58 672 433
Mar 05, 2024 $14.45 $14.84 $14.05 $14.26 816 292
Mar 04, 2024 $15.26 $15.26 $14.30 $14.52 903 798
Mar 01, 2024 $14.91 $16.18 $14.88 $15.28 1 324 872
Feb 29, 2024 $15.99 $16.41 $14.80 $14.91 1 079 987
Feb 28, 2024 $15.24 $18.07 $14.88 $15.49 1 779 098
Feb 27, 2024 $14.42 $14.98 $14.05 $14.71 1 210 016
Feb 26, 2024 $13.53 $14.24 $13.40 $14.08 474 253
Feb 23, 2024 $14.02 $14.63 $13.50 $13.64 1 070 213
Click to get the best stock tips daily for free!

About Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ... ZNTL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT